Keyphrases
Wild-type KRAS
100%
Fcγ Receptor
100%
Metastatic Colorectal Cancer (mCRC)
100%
Receptor Polymorphisms
100%
International Consortium
100%
Cetuximab
100%
Difference in Medians
40%
IgG1 Antibody
20%
Oxaliplatin
20%
Chemotherapy
20%
Response Rate
20%
5-fluorouracil (5-FU)
20%
Irinotecan
20%
Statistical Power
20%
Antibody Response
20%
Receptor Status
20%
Progression-free Survival
20%
Therapeutic Efficacy
20%
Rate Control
20%
Survival Response
20%
Germline Variants
20%
European Centre
20%
Large Cohort
20%
Median Progression-free Survival
20%
Median Overall Survival
20%
Biochemistry, Genetics and Molecular Biology
KRAS
100%
Fc Receptor
100%
Wild Type
100%
Cetuximab
100%
FCGR2A
80%
Progression Free Survival
40%
Germline
20%
Antibody Response
20%
Virus Oncogene
20%
Fluorouracil
20%
Germ Cell
20%
Overall Survival
20%
Sample Size
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
100%
Fc Receptor
100%
Metastatic Colorectal Cancer
100%
Progression Free Survival
40%
Connective Tissue Cancer
20%
Diseases
20%
Combination Therapy
20%
Receptor
20%
Overall Survival
20%
Irinotecan
20%
Fluorouracil
20%
Oxaliplatin
20%
Chemotherapy
20%
Neuroscience
Cetuximab
100%
Fc Receptor
100%
Oxaliplatin
20%
Fluorouracil
20%
Receptor
20%
Virus Oncogene
20%
Germ Cell
20%
Irinotecan
20%